Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100 More than 60% of patients have completed their 6-month treatment plan
Topline results remain on track for year-end
LAVAL, Quebec, June 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (HTG), today announced that the Company’s TRILOGY 2 trial studying CaPre in patients with severe hypertriglyceridemia has achieved 100% patient randomization. This follows the Company’s prior announcement in April 2019 that the Company’s TRILOGY 1 trial had achieved 100% patient randomization.
The Company also announced that its two on-going Phase 3 TRILOGY trials (TRILOGY 1 and TRILOGY 2) have exceeded the target of a combined 500 randomized patients, and more than 60% of the patients in both trials have already completed their 6-month treatment plan.
The fact that both studies have now reached full randomization means that the “last patient, last visit” in the TRILOGY 1 trial is on track to take place in November, and the “last patient, last visit” in the TRILOGY 2 trial is on track to take place in December. It is then anticipated to take approximately 1 month for data clean-up prior to moving to database lock. Once the database is locked, the Company expects topline results for TRILOGY 1 to be released in December 2019 and TRILOGY 2 to be released in January 2020. Topline results will include readout of the primary endpoint, which will show CaPre’s overall impact on lowering triglycerides after 12 weeks. In addition, the topline results will include CaPre’s impact on several important secondary endpoints such as LDL, VLDL and HDL cholesterol and non-HDL cholesterol, as well as HbA1c, an exploratory endpoint which is an important biomarker of glucose control for diabetic patients. The full data set will include results on a number of additional lipid, metabolic and inflammatory markers including CRP, APOA1, APOB, APOA5, APOC3, Lp-PLA2, PCSK9, RLP-C and others. The Company plans to submit the full data set as a late breaker presentation at the American College of Cardiology at the end of March 2020.
Pierre Lemieux, Ph.D., COO and CSO of Acasti, commented, “Both of our TRILOGY Phase 3 trials remain on track and are proceeding according to plan. Consistent with our prior disclosures, there have been no severe adverse events associated with our product to date, and we continue to experience a lower than expected drop-out rate, supporting the high safety profile and patient acceptability of CaPre. Importantly, we are encouraged by the growing excitement within the industry as we eagerly await the results of our TRILOGY program. We appreciate the on-going support of all of the investigators involved with these trials at more than 150 clinical sites across the U.S., Canada, and Mexico.”
About CaPre (omega-3 phospholipid)
Acasti’s prescription drug candidate, CaPre, is a highly purified omega-3 phospholipid concentrate derived from krill oil, and is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. Its omega-3s, principally EPA and DHA, are either “free” or bound to phospholipids, which allows for better absorption into the body. Acasti believes that EPA and DHA are more efficiently transported by phospholipids sourced from krill oil than the EPA and DHA contained in fish oil that are transported either by triglycerides (as in dietary supplements) or as ethyl esters in other prescription omega-3 drugs, which must then undergo additional digestion before they are ready for transport in the bloodstream. Clinically, the phospholipids may not only improve the absorption, distribution, and metabolism of omega-3s, but they may also decrease the synthesis of LDL cholesterol in the liver, impede or block cholesterol absorption, and stimulate lipid secretion from bile. In two Phase 2 studies, CaPre achieved a statistically significant reduction of triglycerides and non-HDL cholesterol levels in patients across the dyslipidemia spectrum from patients with mild to moderate hypertriglyceridemia (patients with TG blood levels between 200mg/dl and 500mg/dl) to patients with severe hypertriglyceridemia (those with TG levels above 500mg/dl). Furthermore, in the Phase 2 studies, CaPre demonstrated the potential to reduce LDL, or “bad cholesterol”, as well as the potential to increase HDL, or “good cholesterol”, especially at the therapeutic dose of 4 grams/day. The Phase 2 data also showed a significant reduction of HbA1c at a 4 gram dose, suggesting that due to its unique omega-3/phospholipid composition, CaPre may actually improve long-term glucose metabolism. Acasti’s TRILOGY Phase 3 program is currently underway.